News & Blog

New Brain Tumor Clinical Trials: January – June 2022

It can be hard to keep track of new clinical trial opportunities opening across the United States. There are many clinical trials actively enrolling patients, and this report provides a summary of the studies that have recently opened or started for primary brain tumor patients*. To learn more about each trial, and to contact the party responsible for enrolling patients, just follow the hyperlink.** To learn more, visit “Information About Clinical Trials” at braintumor.org.


    • A phase I trial to determine the best dose of ibrutinib to use in combination with a previously studied three-drug chemo-immunotherapy regimen (indoximod, cyclophosphamide, and etoposide) for participants, aged 12 to 25 years, with relapsed or refractory ependymoma, medulloblastoma/PNET, or GBM that progressed after previous treatment with indoximod plus temozolomide. 
    • An early phase I study to determine if the drug ketoconazole can enter brain tumors at a high enough amount to stop the tumor cells from dividing. Ketoconazole is a drug that doctors already use for fungal infections and is thought to be able to affect tumor cells.
    • A phase 0 clinical trial to determine if the drug posaconazole can enter brain tumors at a high enough amount to stop the tumor cells from dividing. Posaconazole is a drug that doctors already use for fungal infections and is thought to be able to affect tumor cells.
    • A pilot study of the immunotherapy SurVaxM for children and young adults with progressive or relapsed medulloblastoma, high-grade glioma, ependymoma, and newly diagnosed diffuse intrinsic pontine glioma.
    • A phase 0/Ib study that will enroll at least 14 participants with recurrent WHO Grade IV glioma requiring re-radiation. Patients with tumors demonstrating a positive response in the phase 0 component of the study will graduate to an expansion phase that combines therapeutic dosing of AZD1390 plus standard-of-care fractionated radiotherapy (RT).
    • A phase II study is to determine what effects the drug niraparib has on patients with recurrent brain cancer.
    • A clinical trial to evaluate the safety and side effects of tumor treating fields in patients with gliomas located in the brainstem. 
    • This phase I study is being conducted to determine the dose level for further clinical development of fb-PMT to treat recurrent GBM.
    • This phase I study is looking at the safety and efficacy of the drug combination of ASP8374 with cemiplimab in people with recurrent malignant glioma.
    • The purpose of this early phase I study is to determine if using avatrombopag in patients with thrombocytopenia due to temozolomide treatment can safely improve a patient’s platelet count and allow the patient to complete the temozolomide treatment course as planned.
    • This phase II study will test the safety and effectiveness of a combination of pembrolizumab, olaparib, and temozolomide to see how well these drugs work when given together in people with a glioma that either did not respond to previous treatment or came back after treatment.
    • This is a phase II study of pemigatinib in participants with recurrent GBM or other primary CNS tumors with an activating FGFR1-3 mutation or fusion/rearrangement. 
    • This is a phase I study to evaluate the safety of a type of immunotherapy called HER2 CAR T cells. In addition to looking for side effects, researchers will study how well this treatment works against a brain tumor called ependymoma that has come back after treatment (recurrent) or has not responded well to treatment (progressive) in children. 
    • This clinical study evaluates if a technique/technology called sonobiopsy can enhance a clinician’s insight into the molecular features of a brain tumor to tailor treatment approaches and optimize outcomes. 
    • This is a phase I study investigating the repurposing of the drug chlorpromazine, combined with temozolomide and radiation in the treatment of newly diagnosed GBM.
    • This is a phase I pilot study of C5252 monotherapy designed to determine the safety and tolerability of a single intratumoral injection of C5252 in patients with recurrent or progressive GBM.
    • This is a phase I trial to assess the safety and preliminary efficacy of oral gallium maltolate (GaM) in participants with relapsed GBM.
    • A phase II study investigating the addition of cRIT 131I-omburtamab to irinotecan, temozolomide, and bevacizumab for patients with recurrent medulloblastoma and ependymoma.
    • A phase I/IIa trial to assess the safety and efficacy of CYNK-001 in combination with recombinant human interleukin-2 in adults with recurrent, resection-eligible IDH1 wild-type GBM.
  • A Study to Evaluate ERAS-801 in Patients With Recurrent Glioblastoma (THUNDERBBOLT-1)
    • This is a phase I clinical study evaluating the drug ERAS-801 as a potential new treatment for patients with recurrent GBM harboring alterations in epidermal growth factor receptor (EGFR).
    • This is a single-arm phase II study to determine if the treatment Sacituzumab Govitecan can improve progression-free survival for GBM patients.
    • This is a pilot trial within the Pacific Pediatric Neuro-Oncology Consortium (PNOC)  for relapsed medulloblastoma patients (children and adults), who will receive an individualized treatment recommendation including up to four FDA-approved drugs based on the results of real-time biomarker testing.
    • This is a pilot study to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and the preliminary antitumor activity of BDTX-1535 in patients with GBM harboring EGFR alterations and who have disease progression following standard of care.
    • The purpose of this research study is to see if investigators can predict how brain functioning changes after radiation treatment based on PET scans and blood tests.
    • A phase II study of cabozantinib for patients with recurrent or progressive meningioma.
    • This is a phase II/III trial to investigate the efficacy and safety of REC-2282 in patients with progressive NF2 mutated meningiomas.
    • This trial compares a technology-based supportive cancer care (SCC) approach with a redesigned team-based supportive cancer care (SCC) approach.

*For a comprehensive list of ALL open brain tumor clinical trials, visit the NBTS Clinical Trial Finder at trials.braintumor.org, where you can search for potential opportunities for enrollment based on criteria specific to you.

**For additional navigation support, you can access NBTS’s Personalized Support and Navigation program by emailing patientnavigator@braintumor.org. Learn more here.

 

Post a Comment

Your email is kept private. Required fields are marked *

Share